Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate February 25, 2025
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage February 25, 2025
Neoadjuvant Opdivo® + Chemo Demonstrate Statistically Significant and Clinically Meaningful OS in Resectable NSCLC February 25, 2025
Zongertinib receives Priority Review from US FDA for the treatment of HER2-mutant advanced NSCLC February 25, 2025
EMA approves WELIREG® (belzutifan) for advanced clear cell RCC that progressed following a PD(L)-1 inhibitor and at least two VEGF therapies February 25, 2025
Epitopea Announces License and Research Collaboration Agreement with MSD to Identify CryptigenTM Tumor-Specific Antigens February 25, 2025
Arcus Biosciences Retains Rights to Casdatifan and Announces Pricing of $150 Million Common Stock Offering February 25, 2025
Myris Therapeutics Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer February 25, 2025
Tempus and Stemline Therapeutics Announce Collaboration to Implement Tempus Next to Support Patients with Metastatic Breast Cancer February 25, 2025
Go-ahead obtained to continue enrolling patients in its pancreatic cancer trial (GOBLET Cohort 5) after a positive safety review February 25, 2025
Translational Data Announced from Ph 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer February 25, 2025
Petosemtamab granted Breakthrough Therapy designation by the US FDA for 1L PD-L1 positive head and neck squamous cell carcinoma February 25, 2025
US FDA grants Fast Track Designation to Cu-67 SAR-bisPSMA for the treatment of metastatic CRPC patients February 25, 2025
FDA Acceptance and Priority Review of NDA for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma February 25, 2025
EPKINLY® (epcoritamab) Approved by Japan MHLW for Additional Indication as a Treatment for R/R Follicular Lymphoma February 25, 2025
